益肝散对儿童乙型肝炎病毒感染疗效观察  

Efficacy of hepatitis B virus infection treatment with YIGANSAN in children

作　　者：邹愚[1] 邓存良[1] 

机构地区：[1]泸州医学院附院感染病科,四川泸州646000

出　　处：《中国现代医学杂志》2005年第2期263-265,共3页China Journal of Modern Medicine

摘　　要：目的了解益肝散对儿童乙肝病毒感染的疗效.方法在第4、6月疗程结束时比较益肝散与干扰素对8～14岁儿童乙肝病毒感染的疗效.结果益肝散治疗4个月时综合疗效完全应答率(ALT复常,HBV-DNA及HBeAg阴转)为21.1%,部分应答率为36.8%,血液中HBV-DNA定量由(52.4±38.6)×105cop/mL降为(8.8±7.9)×105 cop/mL,P＜0.01;6月随访时完全应答率为21.1%,部分应答率39.5%,HBV-DNA定量降为(6.9±6.1)×105 cop/mL,与治疗前比P＜0.01.与干扰素治疗相比,治疗4个月时(完全应答率18.4%;部分应答率36.8%;HBV-DNA定量由(51.7±36.8)×105 cop/mL降为(10.1±9.8)×105cop/mL,P＜0.01)无显著差异性(P＞0.05),疗效相当;治疗6个月时[应答率21.1%;部分应答率39.5%;HBV-DNA定量降为(7.8±6.9)×105 cop/mL,与治疗前比P＜0.01]疗效相近(P＞0.05).毒副作用小.结论益肝散对儿童乙肝病毒感染与干扰素有相似效果,治疗安全,是治疗儿童乙肝病毒感染的有效方法.To evaluate the efficacy of YIGANSAN on the children with hepatitis B. The efficacy of YIGANSAN or interferon-α on the 8 to 14 years old children with hepatitis B was observed at the end of 4 and 6 months. The response rate to the treatment at the end of therapy (ALT reply, loss of HBV-DNA and HBeAg) was 21.1%; YIGANSAN lowered HBV-DNA from (52.4±38.6)×105 cop/mL to (8.8±7.9)×105 cop/mL and lowered the expression of HBeAg in the blood, and the part efficacy rate of the treatment at end of therapy is 36.8%, While that of interferon-α was 18.4%, from (51.7±36.8)×105 cop/mL to (10.1±9.8)×105 cop/mL, 36.8%,respectively; there was no significant difference between two groups. The response rate at the end of 6 months was 21.1%; YIGANSAN lowered HBV-DNA to (6.9±6.1)×105 cop/mL, and the part efficacy rate of the end of 6 months is 39.5%, while that of interferon-α are 21.1%, (7.8±6.9)×105 cop/mL, 39.5%, respectively. The side effect of YIGANSAN was less than that of interferon-α. [Conclusion] The efficacy of the YIGANSAN is the same as interferon-α; there is good efficacy of YIGANSAN on the children with hepatitis B. This therapy is safe.

关 键 词：益肝散 儿童 乙肝病毒 疗效 观察 

分 类 号：R512.62[医药卫生—内科学]